TYRO3

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Retrieved on: 
Friday, December 2, 2022
KIT, NSCLC, Receptor tyrosine kinase, VEGFR2, SAPPHIRE, Judgement, TAM, Mer, Large-cell lung carcinoma, Therapy, Cancer, Research, Life, PRMT5, Patient, TYRO3, Science, Lung cancer, SAN, Nivolumab, Pharmaceutical industry, Mirati

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis. The final analysis is expected to be reached in mid-2023.

Key Points: 
  • "We remain committed to developing our portfolio of oncology candidates and advancing our lung cancer strategy to positively impact the lives of patients with cancer.
  • Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12Dinhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.
  • For more information about Mirati Therapeutics, Inc., visit us at Mirati.com or follow us on Twitter and LinkedIn .
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").

Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC

Retrieved on: 
Thursday, June 16, 2022
Antibody, Fibrosis, Cancer, Cirrhosis, RECIST, PD-1, LAG3, Security (finance), Therapy, Safety, Tumor microenvironment, CEO, U.S. Securities and Exchange Commission, Pharmacokinetics, Private Securities Litigation Reform Act, NASDAQ, Roche, LOXL2, SEC, Metastasis, TYRO3, IPF, Patient, Ruxolitinib, Neoplasm, VEGF, Idiopathic pulmonary fibrosis, PD-L1, GLOBE, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, Galecto Biotech, NSCLC

Clinical evidence from patients with NSCLC suggests that high levels of galectin-3 in tumors leads to resistance to treatment with checkpoint inhibitors.

Key Points: 
  • Clinical evidence from patients with NSCLC suggests that high levels of galectin-3 in tumors leads to resistance to treatment with checkpoint inhibitors.
  • In multiple pre-clinical models, including NSCLC, GB1211 has been shown to reduce tumor growth and metastasis and increase efficacy of checkpoint inhibition.
  • Starting in the first-line treatment of NSCLC opens the door for Galecto to pursue numerous oncology opportunities.
  • The Phase 2a trial of GB1211 in combination with Tecentriq will be a 1:1 randomized, double blind, placebo-controlled trial in patients with NSCLC in the first line setting.

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Cancer, Ruxolitinib, LOXL2, TYRO3, Neoplasm, Annual general meeting, Private Securities Litigation Reform Act, Cirrhosis, U.S. Securities and Exchange Commission, Tumor microenvironment, Abstract, Patient, Poster, NASDAQ, PD-1, Antibody, Pharmacokinetics, VEGF, Society, American Society of Clinical Oncology, PD-L1, Metastasis, Fibrosis, ASCO, Large-cell lung carcinoma, Therapy, Idiopathic pulmonary fibrosis, IPF, SEC, LAG3, Security (finance), GLOBE, Pharmaceutical industry, Palladium, NSCLC, Galecto Biotech

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced two poster presentations at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7, 2022 in Chicago, IL.

Key Points: 
  • The abstract will be presented during the poster presentation session on Sunday, June 5, 2022, from 8:00 11:00 am CT (Poster #2607).
  • This trial is designed to investigate the ability of GB1211 to increase the efficacy of checkpoint inhibitors.
  • These posters will be available on Galectos website following presentation at the 2022 ASCO Annual Meeting.
  • Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

AXL Kinase Inhibitor Pipeline Market Report 2022: Insights on 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022
Health, Pharmaceutical, RTK, III, BGB324, Haematopoiesis, HER2, Clinical trial, VEGF, Discovery, PARP, MER, Tyrosine kinase inhibitor, Cell proliferation, TAM, II, KIT, Cancer, TYRO3, PI3K, Tumor microenvironment, Fibrosis, Neoplasm, Drug resistance, AXL, News, Receptor tyrosine kinase, Bemcentinib, VEGFR2, Apoptosis, Therapy, Degenerative disease, EGFR, Pharmaceutical industry

This "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.

Key Points: 
  • This "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.
  • AXL receptor tyrosine Kinase is a member of the tyrosine-protein Kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein Kinase Mer family of receptor tyrosine Kinases.
  • This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e.

Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers

Retrieved on: 
Wednesday, August 25, 2021
Cancer, Judgement, Receptor tyrosine kinase, Twitter, U.S. Securities and Exchange Commission, Therapy, Life, Large-cell lung carcinoma, Survival, SEC, Science, PRMT5, Research, Lung cancer, TAM, VEGFR2, ESMO, KIT, RET, Cetuximab, NASDAQ, Patient, NSCLC, Congress, Solution, LinkedIn, SAN, Mer, Lung, Neoplasm, Colorectal cancer, Pancreatic cancer, TYRO3, Nivolumab, Pharmaceutical industry

We are thankful to the investigators and patients, without whom our research would not be possible."

Key Points: 
  • We are thankful to the investigators and patients, without whom our research would not be possible."
  • Studies of adagrasib have shown that the drug has a long half-life, extensive tissue distribution and is well tolerated.
  • Adagrasib has also shown single-agent responses in non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other solid tumors with KRASG12C mutations.
  • Adagrasib is a being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors.

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Retrieved on: 
Sunday, April 11, 2021
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Tyrosine kinase receptors, Cell signaling, AXL receptor tyrosine kinase, MERTK, Bruton's tyrosine kinase, Tumor microenvironment, Zanubrutinib, Vascular endothelial growth factor, TME, TYRO3, Programmed cell death protein 1, Sitravatinib, Tislelizumab, the Tislelizumab Clinical Program, BeiGene

At the time of data cutoff, 16 patients (64%) remained on study treatment.

Key Points: 
  • At the time of data cutoff, 16 patients (64%) remained on study treatment.
  • The combination of sitravatinib and tislelizumab was generally well tolerated and showed promising antitumor activity among patients with advanced PROC, including those who were heavily pretreated.
  • Sitravatinib targets the VEGFR and TAM (TYRO3, AXL, MERTK) receptor families, which are implicated in orchestrating an immunosuppressive tumor microenvironment (TME).
  • We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA\xc2\xae (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.